Normal immune defence system is vital for health. Overactivity of the immune system leads to the development of autoimmune diseases, such as arthritis, multiple sclerosis and juvenile diabetes. Too weak immune responses, on the other hand, predispose us to cancer and severe bacterial and viral infections. Immunomodulation offers a possibility to treat a wide variety of different diseases, but currently only a small fraction of all patients respond favorably. The InFLAMES Flagship aims at identifying novel drug targets using the most modern technological platforms. It participates in the actual drug development in joint efforts with biotech and pharmaceutical companies. It also invents novel diagnostic tools to identify the patients benefitting from personalized therapies. The Flagship will introduce new avenues for the collaboration between the universities and industry, and will enhance entrepreneurship and the translation of new inventions into commercial products.

2020

2023